28109920|t|Myocardial Blood Flow and Inflammatory Cardiac Sarcoidosis
28109920|a|This study sought to evaluate the effects of inflammatory sarcoid disease on coronary circulatory function and the response to immune-suppressive treatment. Although positron emission tomography assessment of myocardial inflammation is increasingly applied to identify active cardiac sarcoidosis, its effect on coronary flow and immune-suppressive treatment remains to be characterized. Thirty-two individuals, who were referred for positron emission tomography / computed tomography, were evaluated for known or suspected cardiac sarcoidosis applying (18)F-fluorodeoxyglucose to determine inflammation and (13)N-ammonia to assess for perfusion deficits following a high-fat / low-carbohydrate diet and fasting state >12 h to suppress myocardial glucose uptake. Inflammation was quantified with standardized uptake value and regional myocardial blood flow at rest and during regadenoson - stimulated hyperemia was determined in ml/g/min. Positron emission tomography studies were repeated in 18 cases with a median follow-up of 2.5 years (interquartile range [IQR]:1.3 to 3.4 years). Twenty-five exams had normal perfusion but evidence of regional inflammation (group 1), and 21 exams presented a regional perfusion deficit associated with inflammation (group 2). Median myocardial blood flow did not differ between inflamed and noninflamed myocardium in both groups (0.86 ml/g/min [IQR: 0.66 to 1.11 ml/g/min] vs. 0.83 ml/g/min [IQR: 0.64 to 1.12 ml/g/min] and 0.74 ml/g/min [IQR: 0.60 to 0.93 ml/g/min] vs. 0.77 ml/g/min [IQR: 0.59 to 0.95 ml/g/min], respectively). As regards median hyperemic myocardial blood flows, they were significantly lower in the inflamed than in the remote regions in group 1 and 2 (2.31 ml/g/min [IQR: 1.81 to 2.95 ml/g/min] vs. 2.70 ml/g/min [IQR: 2.07 to 3.30 ml/g/min] and 1.61 ml/g/min [IQR: 1.17 to 2.18 ml/g/min] vs. 1.94 ml/g/min [IQR: 1.49 to 2.39 ml/g/min]; p < 0.001, respectively). Immune-suppression -mediated decrease in inflammation was associated with preserved myocardial flow reserve (MFR) at follow-up, whereas MFR significantly worsened in regions without changes or even increases in inflammation (median Δ MFR: 0.07 [IQR: -0.29 to 0.45] vs. -0.24 [IQR: -0.84 to 0.21]; p < 0.001). There was an inverse correlation between pronounced alterations in myocardial inflammation (Δ regional myocardial volume with standardized uptake value >4.1) and Δ MFR (r = -0.47; p = 0.048). Sarcoid -mediated myocardial inflammation is associated with a regional impairment of coronary circulatory function. The association between immune-suppressive treatment -related alterations in myocardial inflammation and changes in coronary vasodilator capacity suggests direct adverse effect of inflammation on coronary circulatory function in cardiac sarcoidosis.
28109920	0	21	Myocardial Blood Flow	T038	UMLS:C2986786
28109920	26	38	Inflammatory	T038	UMLS:C0021368
28109920	39	58	Cardiac Sarcoidosis	T038	UMLS:C0392077
28109920	64	69	study	T062	UMLS:C0008972
28109920	104	116	inflammatory	T038	UMLS:C0021368
28109920	117	132	sarcoid disease	T038	UMLS:C0036202
28109920	136	156	coronary circulatory	T038	UMLS:C0010067
28109920	186	214	immune-suppressive treatment	T058	UMLS:C0021079
28109920	225	253	positron emission tomography	T058	UMLS:C0032743
28109920	268	291	myocardial inflammation	T038	UMLS:C0027059
28109920	328	354	active cardiac sarcoidosis	T038	UMLS:C0392077
28109920	370	383	coronary flow	T038	UMLS:C0010067
28109920	388	416	immune-suppressive treatment	T058	UMLS:C0021079
28109920	457	468	individuals	T098	UMLS:C0237401
28109920	492	520	positron emission tomography	T058	UMLS:C0032743
28109920	523	542	computed tomography	T058	UMLS:C0040405
28109920	582	601	cardiac sarcoidosis	T038	UMLS:C0392077
28109920	611	635	(18)F-fluorodeoxyglucose	T103	UMLS:C0046056
28109920	649	661	inflammation	T038	UMLS:C0021368
28109920	666	679	(13)N-ammonia	T103	UMLS:C1998431
28109920	694	712	perfusion deficits	T033	UMLS:C0428858
28109920	725	733	high-fat	T058	UMLS:C0521974
28109920	736	757	low-carbohydrate diet	T058	UMLS:C0259836
28109920	762	775	fasting state	T033	UMLS:C0015663
28109920	785	793	suppress	T038	UMLS:C0301625
28109920	794	804	myocardial	T017	UMLS:C0027061
28109920	805	819	glucose uptake	T038	UMLS:C1159527
28109920	821	833	Inflammation	T038	UMLS:C0021368
28109920	893	914	myocardial blood flow	T038	UMLS:C2986786
28109920	934	945	regadenoson	T103	UMLS:C1698215
28109920	959	968	hyperemia	T038	UMLS:C0020452
28109920	997	1025	Positron emission tomography	T058	UMLS:C0032743
28109920	1026	1033	studies	T062	UMLS:C0008972
28109920	1074	1083	follow-up	T058	UMLS:C1522577
28109920	1155	1160	exams	T058	UMLS:C0582103
28109920	1172	1181	perfusion	T058	UMLS:C0031001
28109920	1198	1206	regional	T082	UMLS:C0205147
28109920	1207	1219	inflammation	T038	UMLS:C0021368
28109920	1238	1243	exams	T058	UMLS:C0582103
28109920	1256	1264	regional	T082	UMLS:C0205147
28109920	1265	1282	perfusion deficit	T033	UMLS:C0428858
28109920	1299	1311	inflammation	T038	UMLS:C0021368
28109920	1330	1351	myocardial blood flow	T038	UMLS:C2986786
28109920	1375	1383	inflamed	T038	UMLS:C0021368
28109920	1400	1410	myocardium	T017	UMLS:C0027061
28109920	1645	1654	hyperemic	T038	UMLS:C0020452
28109920	1655	1677	myocardial blood flows	T038	UMLS:C2986786
28109920	1716	1724	inflamed	T038	UMLS:C0021368
28109920	1737	1751	remote regions	T082	UMLS:C0205147
28109920	1981	1999	Immune-suppression	T058	UMLS:C0021079
28109920	2022	2034	inflammation	T038	UMLS:C0021368
28109920	2065	2088	myocardial flow reserve	T201	UMLS:C1721077
28109920	2090	2093	MFR	T201	UMLS:C1721077
28109920	2098	2107	follow-up	T058	UMLS:C1522577
28109920	2117	2120	MFR	T201	UMLS:C1721077
28109920	2135	2143	worsened	T033	UMLS:C1457868
28109920	2192	2204	inflammation	T038	UMLS:C0021368
28109920	2215	2218	MFR	T201	UMLS:C1721077
28109920	2357	2380	myocardial inflammation	T038	UMLS:C0027059
28109920	2454	2457	MFR	T201	UMLS:C1721077
28109920	2482	2489	Sarcoid	T038	UMLS:C0392077
28109920	2500	2523	myocardial inflammation	T038	UMLS:C0027059
28109920	2568	2588	coronary circulatory	T038	UMLS:C0010067
28109920	2623	2651	immune-suppressive treatment	T058	UMLS:C0021079
28109920	2676	2699	myocardial inflammation	T038	UMLS:C0027059
28109920	2715	2735	coronary vasodilator	T103	UMLS:C0596385
28109920	2761	2775	adverse effect	T038	UMLS:C0879626
28109920	2779	2791	inflammation	T038	UMLS:C0021368
28109920	2795	2815	coronary circulatory	T038	UMLS:C0010067
28109920	2828	2847	cardiac sarcoidosis	T038	UMLS:C0392077